Press & News

ViewReleaseInStandardHtml

Boule Diagnostics – Information regarding received warning letter from US FDA

Boule Diagnostics AB will hold a conference call to inform about the warning letter Boule have received from FDA.

CEO Fredrik Dalborg and CFO Christina Rubenhag will inform and reply to questions. The presentation will be held in English.

Time:                            13:00 CET, Tuesday, October 09, 2018

Telephone number:     +46(0) 8-744 77 22

Code:                           1212

Please feel free to attend this event!

For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46(0) 705-58 51 05
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46(0) 705-46 72 22

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. www.boule.com  

The information was submitted for publication, through the agency of the contact person set out above, at 11.15 CET on October 8, 2018.